Ryan P - Search Results

1

Representing and utilizing clinical textual data for real world studies: An OHDSI approach.

Keloth VK, Banda JM, Gurley M, Heider PM, Kennedy G, Liu H, Liu F, Miller T, Natarajan K, V Patterson O, Peng Y, Raja K, Reeves RM, Rouhizadeh M, Shi J, Wang X, Wang Y, Wei WQ, Williams AE, Zhang R, Belenkaya R, Reich C, Blacketer C, Ryan P, Hripcsak G, Elhadad N, Xu H. Keloth VK, et al. Among authors: ryan p. J Biomed Inform. 2023 Jun;142:104343. doi: 10.1016/j.jbi.2023.104343. Epub 2023 Mar 17. J Biomed Inform. 2023. PMID: 36935011 Free PMC article.

2

Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership.

Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Stang PE, et al. Ann Intern Med. 2010 Nov 2;153(9):600-6. doi: 10.7326/0003-4819-153-9-201011020-00010. Ann Intern Med. 2010. PMID: 21041580

3

Validation of a common data model for active safety surveillance research.

Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Overhage JM, et al. J Am Med Inform Assoc. 2012 Jan-Feb;19(1):54-60. doi: 10.1136/amiajnl-2011-000376. Epub 2011 Oct 28. J Am Med Inform Assoc. 2012. PMID: 22037893 Free PMC article.

4

Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases.

Reich C, Ryan PB, Stang PE, Rocca M. Reich C, et al. J Biomed Inform. 2012 Aug;45(4):689-96. doi: 10.1016/j.jbi.2012.05.002. Epub 2012 Jun 7. J Biomed Inform. 2012. PMID: 22683994 Free article.

5

Managing data quality for a drug safety surveillance system.

Hartzema AG, Reich CG, Ryan PB, Stang PE, Madigan D, Welebob E, Overhage JM. Hartzema AG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S49-58. doi: 10.1007/s40264-013-0098-7. Drug Saf. 2013. PMID: 24166223

6

Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Reich CG, Ryan PB, Schuemie MJ. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S181-93. doi: 10.1007/s40264-013-0111-1. Drug Saf. 2013. PMID: 24166234

7

The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system.

Reich CG, Ryan PB, Suchard MA. Reich CG, et al. Drug Saf. 2013 Oct;36 Suppl 1:S195-204. doi: 10.1007/s40264-013-0112-0. Drug Saf. 2013. PMID: 24166235

8

Medication-wide association studies.

Ryan PB, Madigan D, Stang PE, Schuemie MJ, Hripcsak G. Ryan PB, et al. CPT Pharmacometrics Syst Pharmacol. 2013 Sep 18;2(9):e76. doi: 10.1038/psp.2013.52. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 24448022 Free PMC article.

9

A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records.

Weng C, Li Y, Ryan P, Zhang Y, Liu F, Gao J, Bigger JT, Hripcsak G. Weng C, et al. Among authors: ryan p. Appl Clin Inform. 2014 May 7;5(2):463-79. doi: 10.4338/ACI-2013-12-RA-0105. eCollection 2014. Appl Clin Inform. 2014. PMID: 25024761 Free PMC article.

10

Fidelity assessment of a clinical practice research datalink conversion to the OMOP common data model.

Matcho A, Ryan P, Fife D, Reich C. Matcho A, et al. Among authors: ryan p. Drug Saf. 2014 Nov;37(11):945-59. doi: 10.1007/s40264-014-0214-3. Drug Saf. 2014. PMID: 25187016 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,553 results

Search Page

Filters